You’re reading the web edition of STAT’s Health Tech newsletter, your guide to how technology is transforming the life sciences. Sign up to get it delivered to your inbox every Tuesday and Thursday.
Good morning, health tech readers!
Breakthrough Summit West: AI in Healthcare Spotlight
In two weeks, we’re holding our Breakthrough Summit West in San Francisco. I’ll be there interviewing OpenEvidence co-founder and CTO Zachary Ziegler. The agenda is packed with insights, and registration is still open.
Continue to STAT+ to read the full story…
Related articles
Ballmaxxing: The Dangerous Testicle Enhancement Trend You Need to Know About
Experts say that “Ballmaxxing” may lead to permanent damage. Image Credit: Heathline/Paloma Rincon Studio/GettyImages Ballmaxxing is the latest social...
STAT Unveils 'The Deadliest Drug' Investigation: Alcohol-Related Deaths Surpass 178,000 Annually in the U.S.
Dear Readers, I want to bring your attention to “The Deadliest Drug,” a new STAT investigative series about our nation’s failure to address excessive...
CDC to Relocate 160+ Monkeys to Sanctuary in Bid to End Animal Testing
As part of efforts to phase out the use of monkeys in research, the Centers for Disease Control and Prevention intends to transfer more than 160 macaq...
Study Links High Air Pollution to Increased Post-Surgical Complications on Utah’s Wasatch Front
New research on Utah’s Wasatch Front—which occasionally experiences the worst air quality in the nation—has found an association between high air poll...
BeOne Secures FDA Approval for Novel Lymphoma Cell Therapy, Advancing Autoimmune Treatment Pipeline
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boo...
Why Major Digital Health Companies Are Absent from Medicare’s Chronic Care Pilot Program
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it deli...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Mid-Stage Trial
Biogen reported mixed results Thursday from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau...